Published by Iain Gilbert on 20th April 2026
(Sharecast News) - Drugmaker AstraZeneca reported positive top-line data from its pivotal Phase III MIRANDA trial on Monday, with first‑in‑class candidate tozorakimab delivering a "statistically significant and clinically meaningful reduction" in the annualised rate of moderate‑to‑severe COPD exacerbations.